Grand Hope’s Artificial Cornea Selected As Innovative Device
This article was originally published in PharmAsia News
The China FDA has selected the new biological artificial cornea of Grand Hope Biotech as an innovative medical device.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.